On 2/21/19 Outlook Therapeutics filed for a $57 million offering in part to support its treatment for wet AMD (age related macular degeneration). The filing did not specify the number of shares to be offered.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,